Weight & Metabolic Health · Data

GLP-1 Weight-Loss Statistics 2026: Every Number, Sourced

By the US Health Digest editorial team · Updated July 26, 2026

The reference numbers on GLP-1 weight-loss medication in one place — usage, trial results, side effects, regain and the regulatory picture — each linked to the trial, poll or regulator it comes from. Cite freely; check us against the sources.

Usage

• 11% of US adults report currently taking a GLP-1 for weight loss as of mid-2026, up from 3% in 2024, per Gallup's May 28–June 5, 2026 survey (n=5,065, ±1.5 points); 15% report ever having used one, and awareness of the drugs has climbed from 80% to 91% since 2024.
• The US adult obesity rate has fallen to 36.4% so far in 2026 from a 39.9% peak in 2022, in the same Gallup tracking — a survey estimate from self-reported height and weight, not clinical measurement; our news analysis covers what those numbers can and cannot show.
• About 1 in 8 US adults (12%) reported having taken a GLP-1 medication back in May 2024, per KFF's national health tracking poll — consistent with Gallup's later trend line.

Efficacy (the pivotal trials)

• Semaglutide 2.4 mg (Wegovy): 14.9% average body-weight loss at 68 weeks, versus 2.4% for placebo, in the 1,961-participant STEP 1 trial — roughly three-quarters of participants were women.
• Tirzepatide (Zepbound): up to 20.9% average loss at 72 weeks on the highest dose in SURMOUNT-1.
• Head-to-head: tirzepatide produced greater average loss than semaglutide over 72 weeks in the first direct comparison trial, published in the NEJM in 2025.
• Full context on what these averages hide: our trial-data breakdown and the Wegovy vs Zepbound comparison.

Side effects and stopping

• 4.5% of semaglutide participants discontinued due to gastrointestinal events (vs 0.8% on placebo) in STEP 1 — GI effects (nausea, diarrhea, constipation) are the dominant side-effect class.
• Weight substantially returns after stopping: in the SURMOUNT-4 withdrawal trial, participants switched to placebo regained much of their lost weight while those continuing kept losing.

The compounding crackdown

• 990 adverse-event reports for compounded semaglutide, plus more than 730 for compounded tirzepatide, had reached the FDA as of May 31, 2026, many involving dosing errors — FDA statement.
• 30 telehealth companies received FDA warning letters in March 2026 over false or misleading compounded-GLP-1 marketing — FDA press release.
• Large-scale GLP-1 compounding is being closed down by FDA rulemaking, per legal analysis of the 2026 proposals. What it means for patients: our explainer.

Marketing reality check

• Weight-loss advertising is unreliable enough that the FTC maintains a published guide to spotting false claims. Any program quoting results should be checked against the trial numbers above.

This page is maintained as a living reference — numbers are updated when the underlying sources change, and the update date above reflects the last review.